Searching...
16 results for “clinical trials”
...clinical trials. And I think that's kinda where the future of the space is going to. The future of pharma is in m and a. I can talk a bit more about why that is, but the larger point here being that we want to be on that forefront.
33:33 / 34:52
from transcript33:33 – 34:52
...clinical trial design, all in parallel, while in SAS, you have to review them in stages. I think what's even more interesting is this whole model of investigator initiated trials, which is actually,
15:42 / 16:47
from transcript15:42 – 16:47
...clinical trials. Clinical trials. Right? Phase one to test for safety and healthy volunteers. Phase two to test for efficacy to see if the drug actually works in small populations with the disease. Phase three to see if that replicates across larger
1:20:05 / 1:21:20
from transcript1:20:05 – 1:21:20
...clinical trials, many of them are failed for reasons beyond just the molecule not being good. For example, the clinical trial might not have been, run the right way, or a company might just have a change in strategic incentives or in strategic alignm
32:31 / 34:07
from transcript32:31 – 34:07
...Clinical trials. Right? Phase one to test for safety and healthy volunteers. Phase two to test for efficacy to see if the drug actually works in small populations with the disease. Phase three to see if that replicates across larger populations and m
1:21:00 / 1:22:04
from transcript1:21:00 – 1:22:04
...the clinical trials to China. That's gonna make a huge impact on the industry. This was actually my next question. I guess, how translatable is a successful clinical trial in China to a market like The US? Three or four years ago, what both investors
33:39 / 34:48
from transcript33:39 – 34:48
...clinical trials. And so it wouldn't be wouldn't really be fair to say that those have contributed already, but they're part of the smoothing function where if you, you know, if you draw a line where you're getting one year per year, they could be par
13:31 / 14:33
from transcript13:31 – 14:33
...clinical trials go phase one, phase two, phase three. Phase one is efficacy. So phase one is safety, and then phase three is ultimately efficacy. This is now past everything. So this would really mean that, actually, this could be approved and on the
48:00 / 49:11
from transcript48:00 – 49:11
...duration clinical trial is a product of scale. You're recruiting tons and tons of people. And the reason you're doing that is to get enough statistical significance that you can show the drug works or not. And that's because you don't know specifical
20:54 / 22:05
from transcript20:54 – 22:05
...pivotal trials for a drug to one pivotal trial for a drug. It's just math. You can achieve the same statistical power if you design one good clinical trial properly with a good control group.
13:29 / 14:30
from transcript13:29 – 14:30
...human clinical trials. Yep. And for those who have heard these phrases before, phase one, phase two, phase three, and never knew what they meant, phase three is the really big, really expensive one. And I'm gonna quote Alex Telford who wrote this rea
1:52:27 / 1:54:09
from transcript1:52:27 – 1:54:09
...trials are going faster than ever. So it used to be ten, twelve years was kind of standard fare, but we now have cases like baby KJ where from birth and diagnosis to cure including FDA approval was seven months. And I think that will increasingly be
14:15 / 15:21
from transcript14:15 – 15:21
...clinical trial design, all in parallel, while in SAS, you have to review them in stages. I think what's even more interesting is this whole model of investigator initiated trials, which is actually, what most people go to, China for. The actual CFDA
16:32 / 17:40
from transcript16:32 – 17:40
or you don't know the mechanism of your drug. And so one of the powers of doing a precision medicine trial is if the drug works, it will tell you that it works or not very early because you've got patients that are supposed to respond genetically to
21:44 / 22:46
from transcript21:44 – 22:46
in currently in clinical trials and that are being used in certain clinics. And there's been a bit of a, pushback, especially amongst the academic community who believe that there needs to be more rigorous data. As a clinician who runs a clinic, what
34:25 / 35:30
from transcript34:25 – 35:30
...trials for a drug to one pivotal trial for a drug. It's just math. You can achieve the same statistical power if you design one good clinical trial properly with a good control group. And so that by the way, that saves like a $100,000,000 to $300,000
14:12 / 15:25
from transcript14:12 – 15:25
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.